Antiepileptics and the treatment of neuropathic pain: Evidence from animal models

Current Pharmaceutical Design

Volumn 11, Issue 23, 2005, Pages 2961-2976

  Blackburn Munro, G ^a   Erichsen, H K ^a  

^a NEUROSEARCH A S   (Denmark)

Author keywords

Allodynia; Anticonvulsant; Channel; GABA; Glutamate; Hyperalgesia; KCNQ; Na+; Nerve injury

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR BLOCKING AGENT; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ARECAIDINE; BENZODIAZEPINE DERIVATIVE; BICUCULLINE; CARBAMAZEPINE; CONANTOKIN G; DIAZEPAM; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; FENTANYL; GABAPENTIN; GLUTAMIC ACID; ION CHANNEL; LAMOTRIGINE; LORAZEPAM; MIBEFRADIL; MUSCIMOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENYTOIN; PLACEBO; RETIGABINE; TIAGABINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ALLODYNIA; CLINICAL TRIAL; DISEASE MODEL; DOSE RESPONSE; DRUG EFFICACY; HUMAN; HYPERALGESIA; NERVE CELL EXCITABILITY; NERVE INJURY; NEUROPATHIC PAIN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SENSORY DYSFUNCTION; TREATMENT OUTCOME;

ANIMALS; ANTICONVULSANTS; DISEASE MODELS, ANIMAL; HUMANS; NEURONS, AFFERENT; PAIN; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 23844508131     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612054865000     Document Type: Review

References (211)

1. Merskey H. IASP Pain Terminology. In: Classification of Chronic Pain, Eds. Merskey H, Bogduk N, IASP Press, Seattle, 1994; 209-14.
2. Verhaak PF, Kerssens JJ, Dekker J, Sorbi MJ, Bensing JM. Prevalence of chronic benign pain disorder among adults: a review of the literature. Pain 1998; 77: 231-9.
3. Jensen TS, Baron R. Translation of symptoms and signs into mechanisms in neuropathic pain. Pain 2003; 102: 1-8.
4. Brattberg G, Thorslund M, Wikman A. The prevalence of pain in a general population. The results of a postal survey in a county of Sweden. Pain 1989; 37: 215-22.
5. Blyth FM, March LM, Brnabic AJ, Jorm LR, Williamson M, Cousins MJ. Chronic pain in Australia: a prevalence study. Pain 2001; 89: 127-34.
6. Von Korff M, Dworkin SF, Le Resche L, Kruger A. An epidemiologic comparison of pain complaints. Pain 1988; 32: 173-83.
7. Stewart WF, Ricci JA, Chee E, Morganstein D, Lipton R. Lost productive time and cost due to common pain conditions in the US workforce. JAMA 2003; 290: 2443-54.
8. Devor M, Seltzer Z. Pathophysiology of damaged nerves in relation to chronic pain. In: Textbook of Pain, Eds. Wall PD, Melzack R, Churchill Livingstone, 1999; 129-64.
9. Arner S, Meyerson BA. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain 1988; 33: 11-24.
10. Rowbotham MC. Efficacy of opioids in neuropathic pain. In: Neuropathic Pain: Pathophysiology and Treatment, Progress in Pain Research and Management, Eds. Hansson PT, Fields HL, Hill RG, Marchettini P. IASP Press, Seattle, 2001; 203-14.
11. Carter GT, Sullivan MD. Antidepressants in pain management. Curr Opin Invest Drugs 2002; 3: 454-8
12. McQuay, H.J. Tramer M, Nye BA, Carroll D, Wiffen PJ, Moore RA. A systematic review of antidepressants in neuropathic pain. Pain 1996; 68: 217-27.
13. Sindrup SH, Jensen TS. Antidepressants in the treatment of neuropathic pain. In: Neuropathic Pain: Pathophysiology and Treatment, Progress in Pain Research and Management, Eds. Hansson PT, Fields HL, Hill RG, Marchettini P. IASP Press, Seattle, 2001; 169-83.
14. Backonja, M. Anticonvulsants and antiarrhythmics in the treatment of neuropathic pain syndromes. In: Neuropathic Pain: Pathophysiology and Treatment, Progress in Pain Research and Management, Eds. Hansson PT, Fields HL, Hill RG, Marchettini P. IASP Press, Seattle, 2001; 185-201.
15. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999; 83: 389-400.
16. Hansson P. Neuropathic pain: clinical characteristics and diagnostic workup. Eur J Pain 2002; 6 Suppl A: 47-50.
17. Otto M, Bak S, Bach FW, Jensen TS, Sindrup SH. Pain phenomena and possible mechanisms in patients with painful polyneuropathy. Pain 2003; 101: 187-92.
18. Galer BS. Neuropathic pain of peripheral origin: advances in pharmacologic treatment. Neurology 1995; 45: S17-25.
19. Attal N. Chronic neuropathic pain: mechanisms and treatment. Clin J Pain 2000; 16: S118-S130.
20. Woolf C J, Bennett GJ, Doherty M, Dubner R, Kidd B, Koltzenburg M, Lipton R, Loeser JD, Payne R, Torebjork E. Towards a mechanism-based classification of pain? Pain 1998; 77: 227-9.
21. Woolf CJ, Decosterd I. Implications of recent advances in the understanding of pain pathophysiology for the assessment of pain in patients. Pain 1999; Suppl 6: S141-7.
22. Dallel R, Voisin D. Towards a pain treatment based on the identification of the pain- generating mechanisms? Eur Neurol 2001; 45: 126-32.
23. Dworkin RH, Backonja M, Rowbotham MC, Allen RR, Argoff CR, Bennett GJ, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol 2003; 60: 1524-34.
24. Soderpalm B. Anticonvulsants: aspects of their mechanisms of action. Eur J Pain 2002; 6 Suppl A: 3-9.
25. Lawson SN. Phenotype and function of somatic primary afferent nociceptive neurones with C-, Adelta- or Aalpha/beta-fibres. Exp Physiol 2002; 87: 239-44.
26. Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science 2000; 288: 1765-9.
27. Julius D, Basbaum AI. Molecular mechanisms of nociception. Nature 2001; 413: 203-10.
28. Burnstock G, Wood JN. Purinergic receptors: their role in nociception and primary afferent neurotransmission. Curr Opin Neurobiol 1996; 6: 526-32.
29. Waldmann R, Lazdunski M. H(+)-gated cation channels: neuronal acid sensors in the NaC/DEG family of ion channels. Curr Opin Neurobiol 1998; 8: 418-24.
30. Costigan M, Woolf CJ. Pain: Molecular Mechanisms. J Pain 2000; 1: 35-44.
31. Jessel TM, Kelly DD. Pain and analgesia. In: Principles of Neural Science, Eds. Kandel ER, Schwartz JH, Jessel TM, Prentice-Hall International Inc, 1991; 385-99.
32. Lembeck F, Donnerer J, Tsuchiya M, Nagahisa A. The non-peptide tachykinin antagonist, CP-96, 345, is a potent inhibitor of neurogenic inflammation. Br J Pharmacol 1992; 105: 527-30.
33. Hunt SP, Mantyh PW. The molecular dynamics of pain control. Nat Rev Neurosci 2001; 2: 83-91.
34. Downing JE, Miyan JA. Neural immunoregulation: emerging roles for nerves in immune homeostasis and disease. Immunol Today 2000; 21: 281-9.
35. Liu CN, Wall PD, Ben-Dor E, Michaelis M, Amir R, Devor M. Tactile allodynia in the absence of C-fiber activation: altered firing properties of DRG neurons following spinal nerve injury. Pain 2000; 85: 503-21.
36. Wall PD, Devor M. Sensory afferent impulses originate from dorsal root ganglia as well as from the periphery in normal and nerve injured rats. Pain 1983; 17: 321-39.
37. Amir R, Liu CN, Kocsis JD, Devor M. Oscillatory mechanism in primary sensory neurones. Brain 2002; 125: 421-35.
38. Amir R, Michaelis M, Devor M. Burst discharge in primary sensory neurons: triggered by subthreshold oscillations, maintained by depolarizing afterpotentials. J Neurosci 2002; 22: 1187-98.
39. Amir R, Michaelis M, Devor M. Membrane potential oscillations in dorsal root ganglion neurons: role in normal electrogenesis and neuropathic pain. J Neurosci 1999; 19: 8589-96.
40. Waxman SG. The molecular pathophysiology of pain: abnormal expression of sodium channel genes and its contributions to hyperexcitability of primary sensory neurons. 1999; Pain Suppl 6: S133-40.
41. Baker MD, Wood JN. Involvement of Na+ channels in pain pathways. Trends Pharmacol Sci 2001; 22: 27-31.
42. Black JA, Dib-Hajj S, Cummins TR, Okuse K, Baker M, Wood JN, et al. Sodium channels as therapeutic targets in neuropathic pain. In: Neuropathic Pain: Pathophysiology and Treatment, Progress in Pain Research and Management, Eds. Hansson PT, Fields HL, Hill RG, Marchettini P. IASP Press, Seattle, 2001; 19-36.
43. Lai J, Hunter JC, Porreca F. The role of voltage-gated sodium channels in neuropathic pain. Curr Opin Neurobiol 2003; 13: 291-7.
44. Waxman SG, Kocsis JD, Black JA. Type III sodium channel mRNA is expressed in embryonic but not adult spinal sensory neurons, and is reexpressed following axotomy. J Neurophysiol 1994; 72: 466-70.
45. Dib-Hajj SD, Fjell J, Cummins TR, Zheng Z, Fried K, LaMotte R, et al. Plasticity of sodium channel expression in DRG neurons in the chronic constriction injury model of neuropathic pain. Pain 1999; 83: 591-600.
46. Decosterd I, Ji RR, Abdi S, Tate S, Woolf CJ. The pattern of expression of the voltage-gated sodium channels Na(v)1.8 and Na(v)1.9 does not change in uninjured primary sensory neurons in experimental neuropathic pain models. Pain 2002; 96: 269-77.
47. Novakovic SD, Tzoumaka E, McGivern JG, Haraguchi M, Sangameswaran L, Gogas KR, et al. Distribution of the tetrodotoxin-resistant sodium channel PN3 in rat sensory neurons in normal and neuropathic conditions. J Neurosci 1998; 18: 2174-87.
48. Coward K, Plumpton C, Facer P, Birch R, Carlstedt T, Tate S, et al. Immunolocalization of SNS/PN3 and NaN/SNS2 sodium channels in human pain states. Pain 2000; 85: 41-50.
49. Novakovic SD, Eglen RM, Hunter JC. Regulation of Na+ channel distribution in the nervous system. Trends Neurosci 2001; 24: 473-8.
50. Lai J, Gold MS, Kim CS, Bian D, Ossipov MH, Hunter JC, et al. Inhibition of neuropathic pain by decreased expression of the tetrodotoxin-resistant sodium channel, NaV1.8. Pain 2002; 95: 143-52.
51. Roza C, Laird JM, Souslova V, Wood JN, Cervero F. The tetrodotoxin-resistant Na+ channel Nav1.8 is essential for the expression of spontaneous activity in damaged sensory axons of mice. J Physiol 2003; 550: 921-6.
52. Gold MS, Shuster MJ, Levine JD. Characterisation of six voltage-gated K+ currents in adult rat sensory neurons. J Neurophysiol 1996; 75: 2629-46.
53. Ishikawa K, Tanaka M, Black JA, Waxman SG. Changes in expression of voltage-gated potassium channels in dorsal root ganglion neurons following axotomy. Muscle Nerve 1999; 22: 502-7.
54. Abdulla FA, Smith PA. Axotomy- and autotomy-induced changes in Ca2+ and K+ channel currents of rat dorsal root ganglion neurons. J Neurophysiol 2001; 85: 644-58.
55. Yang EK, Takimoto K, Hayashi Y, de Groat WC, Yoshimura N. Altered expression of potassium channel subunit mRNA and alpha-dendrotoxin sensitivity of potassium currents in rat dorsal root ganglion neurons after axotomy. Neuroscience 2004; 123: 867-74.
56. Rasband MN, Park EW, Vanderah TW, Lai J, Porreca. F, Trimmer JS. Distinct potassium channels on pain-sensing neurons. Proc Natl Acad Sci USA 2001; 98: 13373-8.
57. Kim DS, Choi JO, Rim HD, Cho HJ. Downregulation of voltage-gated potassium channel alpha gene expression in dorsal root ganglia following chronic constriction injury of the rat sciatic nerve. Brain Res Mol Brain Res 2002; 105: 146-52.
58. Ji RR, Kohno T, Moore KA, Woolf CJ. Central sensitization and LTP: do pain and memory share similar mechanisms ? Trends Neurosci 2003; 26: 696-705
59. Ali Z, Meyer RA, Campbell JN. Secondary hyperalgesia to mechanical but not heat stimuli following a capsaicin injection in hairy skin. Pain 1996; 68: 401-11.
60. Woolf CJ. Generation of acute pain: central mechanisms. Br Med Bull 1991; 47: 523-33.
61. Ji RR, Baba H, Brenner GJ, Woolf CJ. Nociceptive-specific activation of ERK in spinal neurons contributes to pain hypersensitivity. Nat Neurosci 1999; 2: 1114-9.
62. Moore KA, Kohno T, Karchewski LA, Scholz J, Baba H, Woolf CJ. Partial peripheral nerve injury promotes a selective loss of GABAergic inhibition in the superficial dorsal horn of the spinal cord. J Neurosci 2002; 22: 6724-31.
63. Kontinen VK, Stanfa LC, Basu A, Dickenson AH. Electrophysiologic evidence for increased endogenous gabaergic but not glycinergic inhibitory tone in the rat spinal nerve ligation model of neuropathy. Anesthesiology 2001; 94: 333-9.
64. Polgar E, Hughes DI, Riddell JS, Maxwell DJ, Puskar Z, Todd AJ. Selective loss of spinal GABAergic or glycinergic neurons is not necessary for development of thermal hyperalgesia in the chronic constriction injury model of neuropathic pain. Pain 2003; 104: 229-39.
65. Urban MO, Gebhart GF. Supraspinal contributions to hyperalgesia. Proc Natl Acad Sci USA 1999; 96: 7687-92.
66. Craig AD, Dostrovsky JO. From medulla to thalamus: central nervous system mechanisms of pain modulation. In: Textbook of Pain, edn 4. Eds Wall PD, Melzack R. Churchill-Livingstone: Edinburgh; 1999; 183-214.
67. Price DD. Psychological and neural mechanisms of the affective dimension of pain. Science 2000; 288: 1769-72.
68. Salt TE. Glutamate receptor functions in sensory relay in the thalamus. Philos Trans R Soc Lond B Biol Sci 2002; 357: 1759-66.
69. Jasmin L, Rabkin SD, Granato A, Boudah A, Ohara PT. Analgesia and hyperalgesia from GABA-mediated modulation of the cerebral cortex. Nature 2003; 424: 316-20.
70. Milian MJ. Descending control of pain. Prog Neurobiol 2002; 66: 355-474.
71. Fields HL, Basbaum AI. Central nervous system mechanisms of pain modulation. In: Textbook of Pain, edn 4. Eds Wall PD, Melzack R. Churchill-Livingstone: Edinburgh; 1999; 309-30.
72. Ren K, Dubner R. Descending modulation in persistent pain: an update. Pain 2002; 100: 1-6.
73. Blackburn-Munro G. Pain-like behaviours in animals: how human are they? Trends Pharmacol Sci 2004; 25: 299-305.
74. Dubuisson D, Dennis SG. The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats. Pain 1977; 4: 161-74.
75. Tjolsen A, Berge OG, Hunskaar S, Rosland JH, Hole K. The formalin test: an evaluation of the method. Pain 1992; 51: 5-17.
76. Dickenson AH, Sullivan AF. Subcutaneous formal in-induced activity of dorsal horn neurones in the rat: differential response to an intrathecal opiate administered pre or post formalin. Pain 1987; 30: 349-60.
77. Tjolsen A, Hole K. Animal models of analgesia. In: The Pharmacology of Pain, Eds. Dickenson A, Besson JM, pp. Springer, Berlin Heidelberg 1997; 1-20.
78. Yashpal K, Fisher K, Chabot JG, Coderre TJ. Differential effects of NMDA and group I mGluR antagonists on both nociception and spinal cord protein kinase C translocation in the formalin test and a model of neuropathic pain in rats. Pain 2001; 94: 17-29.
79. + channel blockers in the formalin test. Eur J Pharmacol 2002; 445: 225-32.
80. Blackburn-Munro G, Jensen BS. The anticonvulsant retigabine attenuates nociceptive behaviours in rat models of persistent and neuropathic pain. Eur J Pharmacol 2003; 460: 109-16.
81. Blackburn-Munro G, Bomholt SF, Erichsen HK. Behavioural effects of the novel AMPA/GluR5 selective receptor antagonist NS1209 in animal models of experimental pain. Neuropharmacology 2004; 47: 351-62.
82. Walker K, Fox AJ, Urban LA. Animal models for pain research. Mol Med Today 1999; 5: 319-21.
83. Wall PD, Scadding JW, Tomkiewicz MM. The production and prevention of experimental anesthesia dolorosa. Pain 1979; 6: 175-82.
84. Wall PD, Devor M, Inbal R, Scadding JW, Schonfeld D, Seltzer Z, et al. Autotomy following peripheral nerve lesions: experimental anaesthesia dolorosa. Pain 1979; 7: 103-11.
85. Wang LX, Wang ZJ. Animal and cellular models of neuropathic pain. Adv Drug Deliv Rev 2003; 55: 949-65.
86. Choi Y, Yoon YW, Na HS, Kim SH, Chung JM. Behavioral signs of ongoing pain and cold allodynia in a rat model of neuropathic pain. Pain 1994; 59: 369-76.
87. Attal N, Nicholson B, Serra JD. New directions in neuropathic pain: focusing treatment on symptoms and mechanisms. Royal Society of Medicine Press Ltd, 2000; 2-32.
88. Jensen TS, Gottrup H, Sindrup SH, Bach FW. The clinical picture of neuropathic pain. Eur J Pharmacol 2001; 429: 1-11.
89. Elliott AM, Smith BH, Chambers WA. Measuring the severity of chronic pain: a research perspective. Expert Rev Neurotherapeutics 2003; 3: 581-90.
90. Bennett GJ, Xie YK. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 1988; 33: 87-107.
91. Hansson P. Difficulties in stratifying neuropathic pain by mechanisms. Eur J Pain 2003; 7: 353-7.
92. Andersen ML, Tufik S. Sleep patterns over 21-day period in rats with chronic constriction of sciatic nerve. Brain Res 2003; 984: 84-92.
93. Monassi CR, Bandler R, Keay KA. A subpopulation of rats show social and sleep-waking changes typical of chronic neuropathic pain following peripheral nerve injury. Eur J Neurosci 2003; 17: 1907-20.
94. Wilson KG, Eriksson NN, D'Eon JL, Mikail SF, Emery PC. Major depression and insomnia in chronic pain. Clin J Pain 2002; 18: 77-83.
95. Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff GN. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem 1996; 271: 5768-76.
96. Sarantopoulos C, McCallum B, Kwok WM, Hogan Q. Gabapentin decreases membrane calcium currents in injured as well as in control mammalian primary afferent neurons. Reg Anesth Pain Med 2002; 27: 47-57.
97. Luo ZD, Chaplan SR, Higuera ES, Sorkin LS, Stauderman KA, Williams ME, et al. Upregulation of dorsal root ganglion (alpha)2(delta) calcium channel subunit and its correlation with allodynia in spinal nerve-injured rats. J Neurosci 2001; 21: 1868-75.
98. Singh L, Field MJ, Ferris P, Hunter JC, Oles RJ, Williams RG, et al. The antiepileptic agent gabapentin (Neurontin) possesses anxiolytic-like and antinociceptive actions that are reversed by D-serine. Psychopharmacology 1996; 127: 1-9.
99. Field MJ, Oles RJ, Lewis AS, McCleary S, Hughes J, Singh L. Gabapentin (neurontin) and S-(+)-3-isobutylgaba represent a novel class of selective antihyperalgesic agents. Br J Pharmacol 1997; 121: 1513-22.
100. Shimoyama N, Shimoyama M, Davis AM, Inturrisi CE, Elliott KJ. Spinal gabapentin is antinociceptive in the rat formalin test. Neurosci Lett 1997; 222: 65-7.
101. Abdi S, Lee DH, Chung JM. The anti-allodynic effects of amitriptyline, gabapentin, and lidocaine in a rat model of neuropathic pain. Anesth Analg 1998; 87: 1360-6.
102. Hunter JC, Gogas KR, Hedley LR, Jacobson LO, Kassotakis L, Thompson J, et al. The effect of novel anti-epileptic drugs in rat experimental models of acute and chronic pain. Eur J Pharmacol 1997; 324: 153-60.
103. Chapman V, Suzuki R, Chamarette HL, Rygh LJ, Dickenson AE. Effects of systemic carbamazepine and gabapentin on spinal neuronal responses in spinal nerve ligated rats. Pain 1998; 75: 261-72.
104. Field MJ, McCleary S, Hughes J, Singh L. Gabapentin and pregabalin, but not morphine and amitriptyline, block both static and dynamic components of mechanical allodynia induced by streptozocin in the rat. Pain 1999; 80: 391-8.
105. Pan HL, Eisenach JC, Chen SR. Gabapentin suppresses ectopic nerve discharges and reverses allodynia in neuropathic rats. J Pharmacol Exp Ther 1999; 288: 1026-30.
106. Field MJ, Hughes J, Singh L. Further evidence for the role of the alpha(2)delta subunit of voltage dependent calcium channels in models of neuropathic pain. Br J Pharmacol 2000; 131: 282-6.
107. Corradini L, Briscini L, Ongini E, Bertorelli R. The putative OP(4) antagonist, [Nphe(1)]nociceptin(1-13)NH(2), prevents the effects of nociceptin in neuropathic rats. Brain Res 2001; 905: 127-33.
108. Field MJ, Gonzalez MI, Tallarida RJ, Singh L. Gabapentin and the neurokinin(1) receptor antagonist CI-1021 act synergistically in two rat models of neuropathic pain. J Pharmacol Exp Ther 2002; 303: 730-5.
109. Luo ZD, Calcutt NA, Higuera ES, Valder CR, Song YH, Svensson CI, et al. Injury type-specific calcium channel alpha 2 delta-1 subunit up-regulation in rat neuropathic pain models correlates with antiallodynic effects of gabapentin. J Pharmacol Exp Ther 2002; 303: 1199-205.
110. Erichsen HK, Blackburn-Munro G. Pharmacological characterisation of the spared nerve injury model of neuropathic pain. Pain 2002; 98: 151-61.
111. Patel S, Naeem S, Kesingland A, Froesd W, Capogna M, Urban L, et al. The effects of GABA(B) agonists and gabapentin on mechanical hyperalgesia in models of neuropathic and inflammatory pain in the rat. Pain 2001; 90: 217-26.
112. Fox A, Gentry C, Patel S, Kesingland A, Bevan S. Comparative activity of the anti-convulsants oxcarbazepine, carbamazepine, lamotrigine and gabapentin in a model of neuropathic pain in the rat and guinea-pig. Pain 2003; 105: 355-62.
113. Laughlin TM, Tram KV, Wilcox GL, Birnbaum AK. Comparison of antiepileptic drugs tiagabine, lamotrigine, and gabapentin in mouse models of acute, prolonged, and chronic nociception. J Pharmacol Exp Ther 2002; 302: 1168-75.
114. Hao JX, Xu XJ, Urban L, Wiesenfeld-Hallin Z. Repeated administration of systemic gabapentin alleviates allodynia-like behaviors in spinally injured rats. Neurosci Lett 2000; 280: 211-4.
115. Hulsebosch CE, Xu GY, Perez-Polo JR, Westlund KN, Taylor CP, McAdoo DJ. Rodent model of chronic central pain after spinal cord contusion injury and effects of gabapentin. J Neurotrauma 2000; 17: 1205-17.
116. Takasaki I, Andoh T, Nojima H, Shiraki K, Kuraishi Y. Gabapentin antinociception in mice with acute herpetic pain induced by herpes simplex virus infection. J Pharmacol Exp Ther 2001; 296: 270-5.
117. Christensen D, Gautron M, Guilbaud G, Kayser V. Effect of gabapentin and lamotrigine on mechanical allodynia-like behaviour in a rat model of trigeminal neuropathic pain. Pain. 2001; 93: 147-53.
118. Hwang JH, Yaksh TL. Effect of subarachnoid gabapentin on tactile-evoked allodynia in a surgically induced neuropathic pain model in the rat. Reg Anesth 1997; 22: 249-56.
119. Chen SR, Eisenach JC, McCaslin PP, Pan HL. Synergistic effect between intrathecal non-NMDA antagonist and gabapentin on allodynia induced by spinal nerve ligation in rats. Anesthesiology. 2000; 92: 500-6.
120. Cho HS, Kim MH, Choi DH, Lee JI, Gwak MS, Hahm TS. The effect of intrathecal gabapentin on mechanical and thermal hyperalgesia in neuropathic rats induced by spinal nerve ligation. J Korean Med Sci 2002; 17: 225-9.
121. Wallin J, Cui JG, Yakhnitsa V, Schechtmann G, Meyerson BA, Linderoth B. Gabapentin and pregabalin suppress tactile allodynia and potentiate spinal cord stimulation in a model of neuropathy. Eur J Pain 2002; 6: 261-72.
122. Carbone E, Lux HD. A low voltage-activated, fully inactivating Ca channel in vertebrate sensory neurones. Nature 1984; 310: 501-2.
123. Todorovic SM, Meyenburg A, Jevtovic-Todorovic V. Mechanical and thermal antinociception in rats following systemic administration of mibefradil, a T-type calcium channel blocker. Brain Res 2002; 951: 336-40.
124. Todorovic SM, Lingle CJ. Pharmacological properties of T-type Ca2+ current in adult rat sensory neurons: effects of anticonvulsant and anesthetic agents. J Neurophysiol 1998; 79: 240-52.
125. Matthews EA, Dickenson AH. Effects of ethosuximide, a T-type Ca(2+) channel blocker, on dorsal horn neuronal responses in rats. Eur J Pharmacol 2001; 415: 141-9.
126. Dogrul A, Gardell LF, Ossipov MH, Tulunay FC, Lai J, Porreca F. Reversal of experimental neuropathic pain by T-type calcium channel blockers. Pain 2003; 105: 159-68.
127. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res 2002; 51: 31-71.
128. Sobieszek G, Borowicz KK, Kimber-Trojnar Z, Malek R, Piskorska B, Czuczwar SJ. Zonisamide: a new antiepileptic drug. Pol J Pharmacol 2003; 55: 683-9.
129. Schauf CL. Zonisamide enhances slow sodium inactivation in Myxicola. Brain Res 1987; 413: 185-8.
130. Rock DM, Macdonald RL, Taylor CP. Blockade of sustained repetitive action potentials in cultured spinal cord neurons by zonisamide (AD 810, CI 912), a novel anticonvulsant. Epilepsy Res 1989; 3: 138-43.
131. Suzuki S, Kawakami K, Nishimura S, Watanabe Y, Yagi K, Seino M, et al. Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Res 1992; 12: 21-7.
132. Kito M, Maehara M, Watanabe K. Mechanisms of T-type calcium channel blockade by zonisamide. Seizure 1996; 5: 115-9.
133. Hord AH, Denson DD, Chalfoun AG, Azevedo MI. The effect of systemic zonisamide (Zonegran) on thermal hyperalgesia and mechanical allodynia in rats with an experimental mononeuropathy. Anesth Analg 2003; 96: 1700-6.
134. Leach JP, Brodie MJ. New antiepileptic drugs-an explosion of activity. Seizure 1995; 4: 5-17.
135. Xie XM, Date TJ, Trezise DJ. Voltage-dependent inhibition of tetrodotoxin-resistant Na+ currents in rat sensory neurons by lamotrigine. Soc Neurosci Abstr 1996; 22: 33.3.
136. Xie XM, John VH, Trezise DJ. Inhibitory effects of lamotrigine on action potential firing in rat sensory neurons in vitro. Soc Neurosci Abstr 1997; 23: 445.3.
137. +-channel blockers on somatosensory processing by rat dorsal horn neurones. NeuroReport 1997; 8: 1549-54.
138. Blackburn-Munro G, Dickinson T, Fleetwood-Walker SM. Non-opioid actions of lamotrigine within the rat dorsal horn after inflammation and neuropathic nerve damage. Neurosci Res 2001; 39: 385-90.
139. Chapman V, Wildman MA, Dickenson AH. Distinct electrophysiological effects of two spinally administered membrane stabilising drugs, bupivacaine and lamotrigine. Pain 1997; 71: 285-95.
140. Nakamura-Craig M, Follenfant RL. Effect of lamotrigine in the acute and chronic hyperalgesia induced by PGE2 and in the chronic hyperalgesia in rats with streptozotocin-induced diabetes. Pain 1995; 63: 33-7.
141. + channel blockers in two rat models of neuropathic pain. Eur J Pharmacol 2003; 458: 275-82.
142. Cereghino JJ, Biton V, Abou-Khalil B, Dreifuss F, Gauer LJ, Leppik I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000; 55: 236-42.
143. Zona C, Niespodziany I, Marchetti C, Klitgaard H, Bernardi G, Margineanu DG. Levetiracetam does not modulate neuronal voltage-gated Na+ and T-type Ca2+ currents. Seizure 2001; 10: 279-86.
144. Niespodziany I, Klitgaard H, Margineanu DG. Levetiracetam inhibits the high-voltage-activated Ca(2+) current in pyramidal neurones of rat hippocampal slices. Neurosci Lett 2001; 306: 5-8.
145. Lukyanetz EA, Shkryl VM, Kostyuk PG. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia 2002; 43: 9-18.
146. Rigo JM, Hans G, Nguyen L, Rocher V, Belachew S, Malgrange B, et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br J Pharmacol 2002; 136: 659-72.
147. Ardid D, Lamberty Y, Alloui A, Coudore-Civiale MA, Klitgaard H, Eschalier A. Antihyperalgesic effect of levetiracetam in neuropathic pain models in rats. Eur J Pharmacol 2003; 473: 27-33.
148. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V). Epilepsy Res 2001; 43: 11-58.
149. Stefani A, Calabresi P, Pisani A, Mercuri NB, Siniscalchi A, Bernardi G. Felbamate inhibits dihydropyridine-sensitive calcium channels in central neurons. J Pharmacol Exp Ther 1996; 277: 121-7.
150. Taglialatela M, Ongini E, Brown AM, Di Renzo G, Annunziato L. Felbamate inhibits cloned voltage-dependent Na+ channels from human and rat brain. Eur J Pharmacol 1996; 316: 373-7.
151. Kleckner NW, Glazewski JC, Chen CC, Moscrip TD. Subtype-selective antagonism of N-methyl-D-aspartate receptors by felbamate: insights into the mechanism of action. J Pharmacol Exp Ther 1999; 289: 886-94.
152. Imamura Y, Bennett GJ. Felbamate relieves several abnormal pain sensations in rats with an experimental peripheral neuropathy. J Pharmacol Exp Ther 1995; 275: 177-82.
153. Adusumalli VE, Yang JT, Wong KK, Kucharczyk N, Sofia RD. Felbamate pharmacokinetics in the rat, rabbit, and dog. Drug Metab Dispos 1991; 19: 1116-25.
154. Donevan SD, McCabe RT. Conantokin G is an NR2B-selective competitive antagonist of N-methyl-D-aspartate receptors. Mol Pharmacol 2000; 58: 614-23.
155. MaImberg AB, Gilbert H, McCabe RT, Basbaum AI. Powerful antinociceptive effects of the cone snail venom-derived subtype-selective NMDA receptor antagonists conantokins G and T. Pain 2003; 101: 109-16.
156. Nielsen EB, Suzdak PD, Andersen KE, Knutsen LJ, Sonnewald U, Braestrup C. Characterization of tiagabine (NO-328), a new potent and selective GABA uptake inhibitor. Eur J Pharmacol 1991; 196: 257-66.
157. Fink-Jensen A, Suzdak PD, Swedberg MD, Judge ME, Hansen L, Nielsen PG. The gamma-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats. Eur J Pharmacol 1992; 220: 197-201.
158. Giardina WJ, Decker MW, Porsolt RD, Roux S, Collins SD, Kim DJ, et al. An evaluation of the GABA uptake blocker tiagabine in animal models of nociceptive and neuropathic pain. Drug Dev Res 1998; 44: 106-13.
159. Ipponi A, Lamberti C, Medica A, Bartolini A, Malmberg-Aiello P. Tiagabine antinociception in rodents depends on GABA(B) receptor activation: parallel antinociception testing and medial thalamus GABA microdialysis. Eur J Pharmacol 1999; 368: 205-11.
160. Laughlin TM, Vanderah TW, Lashbrook J, Nichols ML, Ossipov M, Porreca F, et al. Spinally administered dynorphin A produces long-lasting allodynia: involvement of NMDA but not opioid receptors. Pain 1997; 72: 253-60.
161. Czuczwar M, Kis J, Potasinski A, Turski WA, Przesmycki K. Isobolographic analysis of interaction between vigabatrin and baclofen in the formalin test in mice. Pol J Pharmacol 2001; 53: 527-30.
162. Alves ND, de Castro-Costa CM, de Carvalho AM, Santos FJ, Silveira DG. Possible analgesic effect of vigabatrin in animal experimental chronic neuropathic pain. Arq Neuropsiquiatr 1999; 57: 916-20.
163. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 2002; 16: 695-714.
164. Johannessen CU, Johannessen SI. Valproate: past, present, and future. CNS Drug Rev 2003; 9: 199-216.
165. Czuczwar M, Kis J, Swiader M, Turski WA, Przesmycki K. Evaluation of interaction between valproate and baclofen in the formalin test in mice. Pol J Pharmacol 2001; 53: 51-4.
166. Cutrer FM, Moskowitz MA. Wolff Award 1996. The actions of valproate and neurosteroids in a model of trigeminal pain. Headache 1996; 36: 579-85.
167. Gribkoff VK. The therapeutic potential of neuronal KCNQ channel modulators. Expert Opin Ther Targets 2003; 7: 73748.
168. Rundfeldt C, Netzer R. The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells transfected with human KCNQ2/3 subunits. Neurosci Lett 2000; 282: 73-6.
169. Tatulian L, Delmas P, Abogadie FC, Brown DA. Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine. J Neurosci 2001; 21: 5535-45.
170. Jentsch T. Neuronal KCNQ potassium channels: physiology and role in disease. Nat Rev Neurosci 2000; 1; 21-30.
171. Rogawski MA. KCNQ2/KCNQ3 K+ channels and the molecular pathogenesis of epilepsy: implications for therapy. Trends Neurosci 2000; 23: 393-8.
172. Devaux JJ, Kleopa KA, Cooper EC, Scherer SS. KCNQ2 is a nodal K+ channel. J Neurosci 2004; 24: 1236-44.
173. Passmore GM, Selyanko AA, Mistry M, Al-Qatari M, Marsh SJ, Matthews EA, et al. KCNQ/M currents in sensory neurons: significance for pain therapy. J Neurosci 2003; 23: 7227-36.
174. Nielsen, AN, Mathiesen, C, Blackburn-Munro G. Pharmacological characterisation of acid-induced muscle allodynia in rats. Eur J Pharmacol-2004; 487: 93-103.
175. Brodie MJ, Dichter MA. Antiepileptic drugs. N Engi J Med 1996; 334: 168-75.
176. Treiman DM, Meyers PD, Walton NY, Collins JF, Coiling C, Rowan AJ, et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med 1998; 339: 792-8.
177. Ibuki T, Hama AT, Wang XT, Pappas GD, Sagen J. Loss of GABA-immunoreactivity in the spinal dorsal hom of rats with peripheral nerve injury and promotion of recovery by adrenal medullary grafts. Neuroscience 1997; 76: 845-58.
178. Obata K, Yamanaka H, Fukuoka T, Yi D, Tokunaga A, Hashimoto N, et al. Contribution of injured and uninjured dorsal root ganglion neurons to pain behavior and the changes in gene expression following chronic constriction injury of the sciatic nerve in rats. Pain 2003; 101: 65-77.
179. Baba H, Ji RR, Kohno T, Moore KA, Ataka T, Wakai A, et al. Removal of GABAergic inhibition facilitates polysynaptic A fiber-mediated excitatory transmission to the superficial spinal dorsal horn. Mol Cell Neurosci 2003; 24: 818-30.
180. Kontinen VK, Dickenson AH. Effects of midazolam in the spinal nerve ligation model of neuropathic pain in rats. Pain 2000; 85: 425-31.
181. Malan TP, Mata HP, Porreca F. Spinal GABA(A) and GABA(B) receptor pharmacology in a rat model of neuropathic pain. Anesthesiology 2002; 96: 1161-7.
182. Hwang JH, Yaksh TL. The effect of spinal GABA receptor agonists on tactile allodynia in a surgically-induced neuropathic pain model in the rat. Pain 1997; 70: 15-22.
183. Max MB, Schafer SC, Culnane M, Smoller B, Dulmer R, Gracely RH. Amitriptyline, but not lorazepam, relieves postherpetic neuralgia. Neurology. 1988; 38: 1427-32.
184. Dellemijn PL, Vanneste JA. Randomised double-blind active-placebo-contro lied crossover trial of intravenous fentanyl in neuropathic pain. Lancet 1997; 349: 753-8.
185. Sang CN, Booher S, Gilron I, Parada S, Max MB. Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose-response trials. Anesthesiology 2002; 96: 1053-61.
186. Seltzer Z, Dubner R, Shir Y. A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain 1990; 43: 205-18.
187. Kim SH, Chung JM. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 1992; 50: 355-63.
188. Decosterd I, Woolf CJ. Spared nerve injury: an animal model of persistent peripheral neuropathic pain. Pain 2000; 87: 149-58.
189. Vos BP, Strassman AM, Maciewicz RJ. Behavioral evidence of trigeminal neuropathic pain following chronic constriction injury to the rat's infraorbital nerve. J Neurosci 1994; 14: 2708-23.
190. Courteix C, Eschalier A, Lavarenne J. Streptozotocin-induced diabetic rats: behavioural evidence for a model of chronic pain. Pain 1993; 53: 81-8.
191. Aley KO, Reichling DB, Levine JD. Vincristine hyperalgesia in the rat: a model of painful vincristine neuropathy in humans. Neuroscience 1996; 73: 259-65.
192. Authier N, Gillet JP, Fialip J, Eschalier A, Coudore F. Description of a short-term Taxol-induced nociceptive neuropathy in rats. Brain Res 2000; 887: 239-49.
193. Xu XJ, Hao JX, Aldskogius H, Seiger A, Wiesenfeld-Hallin Z. Chronic pain-related syndrome in rats after ischemic spinal cord lesion: a possible animal model for pain in patients with spinal cord injury. Pain 1992; 48: 279-90.
194. Kehl LJ, Hamamoto DT, Wacnik PW, Croft DL, Norsted BD, Wilcox GL, et al. A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain. Pain 2003; 103: 175-86.
195. Shimoyama M, Tanaka K, Hasue F, Shimoyama N. A mouse model of neuropathic cancer pain. Pain; 2002 99: 167-74.
196. Fleetwood-Walker SM, Quinn JP, Wallace C, Blackburn-Munro G, Kelly BG, Fiskerstrand CE, et al. Behavioural changes in the rat following infection with varicella-zoster virus. J Gen Virol 1999; 80: 2433-6.
197. Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998; 280: 1831-6.
198. Morello CM, Leckband SG, Stoner CP, Moorhouse DF, Sahagian GA. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med 1999; 159: 1931-7.
199. Backonja MM. Use of anticonvulsants for treatment of neuropathic pain. Neurology 2002; 59(5 Suppl 2): S14-7.
200. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998; 280: 1837-42.
201. Zakrzewska JM, Chaudhry Z, Nurmikko TJ, Patton DW, Mullens EL. Lamotrigine (lamictal) in refractory trigeminal neuralgia: results from a double-blind placebo controlled crossover trial. Pain 1997; 73: 223-30.
202. Sandner-Kiesling A, Rumpold Seitlinger G, Dorn C, Koch H, Schwarz G. Lamotrigine monotherapy for control of neuralgia after nerve section. Acta Anaesthesiol Scand 2002; 46: 1261-4.
203. Vestergaard K, Andersen G, Gottrup H, Kristensen BT, Jensen TS. Lamotrigine for central poststroke pain: a randomized controlled trial. Neurology 2001; 56: 184-90.
204. Simpson DM, Olney R, McArthur JC, Khan A, Godbold J, Ebel-Frommer K. A placebo-controlled trial of lamotrigine for painful HIV-associated neuropathy. Neurology 2000; 54: 2115-9.
205. Price MJ. Levetiracetam in the treatment of neuropathic pain: three case studies. Clin J Pain 2004; 20: 33-6.
206. Kochar DK, Rawat N, Agrawal RP, Vyas A, Beniwal R, Kochar SK, et al. Sodium valproate for painful diabetic neuropathy: a randomized double-blind placebo-controlled study. QJM 2004; 97:33-8.
207. Novak V, Kanard R, Kissel JT, Mendell JR. Treatment of painful sensory neuropathy with tiagabine: a pilot study. Clin Auton Res 2001; 11: 357-61.
208. Backonja M, Glanzman RL. Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. Clin Ther 2003; 25: 81-104.
209. Gomtsyan A, Lee CH. Nonnucleoside inhibitors of adenosine kinase. Curr Pharm Design 2004; 10(10): 1093-103.
210. Ravert HT, Bencherif B, Madar I, Frost JJ. PET imaging of opioid receptors in pain: progress and new directions. Curr Pharm Design 2004; 10(7): 759-68.
211. Sabatowski R, Schafer D, Kasper SM, Brunsch H, Radbruch L. Pain treatment: a historical overview. Curr Pharm Design 2004; 10(7): 701-16.